These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 27866774)

  • 1. Complement-independent dengue virus type 1 infection-enhancing antibody reduces complement-dependent and -independent neutralizing antibody activity.
    Yamanaka A; Konishi E
    Vaccine; 2016 Dec; 34(51):6449-6457. PubMed ID: 27866774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dengue-Immune Humans Have Higher Levels of Complement-Independent Enhancing Antibody than Complement-Dependent Neutralizing Antibody.
    Yamanaka A; Konishi E
    Jpn J Infect Dis; 2017 Sep; 70(5):579-581. PubMed ID: 28367878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A mouse monoclonal antibody against dengue virus type 1 Mochizuki strain targeting envelope protein domain II and displaying strongly neutralizing but not enhancing activity.
    Yamanaka A; Kotaki T; Konishi E
    J Virol; 2013 Dec; 87(23):12828-37. PubMed ID: 24049185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dengue virus infection-enhancing and neutralizing antibody balance in children of the Philippines and Indonesia.
    Yamanaka A; Tabuchi Y; Mulyatno KC; Susilowati H; Hendrianto E; Soegijanto S; Konishi E
    Microbes Infect; 2012 Nov; 14(13):1152-9. PubMed ID: 22841680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of enhancing-activity-free neutralizing antibody against dengue type 1 virus in plasmid-inoculated mice.
    Yamanaka A; Pitaksajjakul P; Ramasoota P; Konishi E
    Vaccine; 2015 Nov; 33(45):6070-7. PubMed ID: 26259543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Balance of infection-enhancing and neutralizing antibodies induced by a dengue tetravalent DNA vaccine in a mouse model.
    Konishi E; Miyagawa Y
    Microbes Infect; 2011 Nov; 13(12-13):1091-8. PubMed ID: 21763777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation of Monoclonal Antibodies against Dengue Virus Type 4 and Identification of Enhancing Epitopes on Envelope Protein.
    Tang CT; Liao MY; Chiu CY; Shen WF; Chiu CY; Cheng PC; Chang GJ; Wu HC
    PLoS One; 2015; 10(8):e0136328. PubMed ID: 26309127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of single-round infectious, chimeric dengue type 1 virus as an antigen for dengue functional antibody assays.
    Yamanaka A; Suzuki R; Konishi E
    Vaccine; 2014 Jul; 32(34):4289-95. PubMed ID: 24950360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infection-enhancing and -neutralizing activities of mouse monoclonal antibodies against dengue type 2 and 4 viruses are controlled by complement levels.
    Yamanaka A; Kosugi S; Konishi E
    J Virol; 2008 Jan; 82(2):927-37. PubMed ID: 18003724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dengue virus neutralization and antibody-dependent enhancement activities of human monoclonal antibodies derived from dengue patients at acute phase of secondary infection.
    Sasaki T; Setthapramote C; Kurosu T; Nishimura M; Asai A; Omokoko MD; Pipattanaboon C; Pitaksajjakul P; Limkittikul K; Subchareon A; Chaichana P; Okabayashi T; Hirai I; Leaungwutiwong P; Misaki R; Fujiyama K; Ono K; Okuno Y; Ramasoota P; Ikuta K
    Antiviral Res; 2013 Jun; 98(3):423-31. PubMed ID: 23545366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic efficacy of antibodies lacking Fcγ receptor binding against lethal dengue virus infection is due to neutralizing potency and blocking of enhancing antibodies [corrected].
    Williams KL; Sukupolvi-Petty S; Beltramello M; Johnson S; Sallusto F; Lanzavecchia A; Diamond MS; Harris E
    PLoS Pathog; 2013 Feb; 9(2):e1003157. PubMed ID: 23459315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The potent and broadly neutralizing human dengue virus-specific monoclonal antibody 1C19 reveals a unique cross-reactive epitope on the bc loop of domain II of the envelope protein.
    Smith SA; de Alwis AR; Kose N; Harris E; Ibarra KD; Kahle KM; Pfaff JM; Xiang X; Doranz BJ; de Silva AM; Austin SK; Sukupolvi-Petty S; Diamond MS; Crowe JE
    mBio; 2013 Nov; 4(6):e00873-13. PubMed ID: 24255124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. B Cell Responses during Secondary Dengue Virus Infection Are Dominated by Highly Cross-Reactive, Memory-Derived Plasmablasts.
    Priyamvada L; Cho A; Onlamoon N; Zheng NY; Huang M; Kovalenkov Y; Chokephaibulkit K; Angkasekwinai N; Pattanapanyasat K; Ahmed R; Wilson PC; Wrammert J
    J Virol; 2016 Jun; 90(12):5574-85. PubMed ID: 27030262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of infection-neutralizing and -enhancing antibody balance induced by two distinct genotype strains of dengue virus type 1 or 3 DNA vaccines in mice.
    Sjatha F; Takizawa Y; Kotaki T; Yamanaka A; Konishi E
    Microbes Infect; 2013 Nov; 15(12):828-36. PubMed ID: 23911844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel reporter system for neutralizing and enhancing antibody assay against dengue virus.
    Song KY; Zhao H; Jiang ZY; Li XF; Deng YQ; Jiang T; Zhu SY; Shi PY; Zhang B; Zhang FC; Qin ED; Qin CF
    BMC Microbiol; 2014 Feb; 14():44. PubMed ID: 24548533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody with an engineered Fc region as a therapeutic agent against dengue virus infection.
    Ramadhany R; Hirai I; Sasaki T; Ono K; Ramasoota P; Ikuta K; Kurosu T
    Antiviral Res; 2015 Dec; 124():61-8. PubMed ID: 26522769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virus-like particles derived from Pichia pastoris-expressed dengue virus type 1 glycoprotein elicit homotypic virus-neutralizing envelope domain III-directed antibodies.
    Poddar A; Ramasamy V; Shukla R; Rajpoot RK; Arora U; Jain SK; Swaminathan S; Khanna N
    BMC Biotechnol; 2016 Jun; 16(1):50. PubMed ID: 27301568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dengue Virus Infection with Highly Neutralizing Levels of Cross-Reactive Antibodies Causes Acute Lethal Small Intestinal Pathology without a High Level of Viremia in Mice.
    Watanabe S; Chan KW; Wang J; Rivino L; Lok SM; Vasudevan SG
    J Virol; 2015 Jun; 89(11):5847-61. PubMed ID: 25787279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An Epitope-Substituted DNA Vaccine Improves Safety and Immunogenicity against Dengue Virus Type 2.
    Tang CT; Li PC; Liu IJ; Liao MY; Chiu CY; Chao DY; Wu HC
    PLoS Negl Trop Dis; 2015; 9(7):e0003903. PubMed ID: 26135599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanistic study of broadly neutralizing human monoclonal antibodies against dengue virus that target the fusion loop.
    Costin JM; Zaitseva E; Kahle KM; Nicholson CO; Rowe DK; Graham AS; Bazzone LE; Hogancamp G; Figueroa Sierra M; Fong RH; Yang ST; Lin L; Robinson JE; Doranz BJ; Chernomordik LV; Michael SF; Schieffelin JS; Isern S
    J Virol; 2013 Jan; 87(1):52-66. PubMed ID: 23077306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.